Zhuhai Rundu Pharmaceutical Co. Ltd. Class A

As of June 30, 2026, Zhuhai Rundu Pharmaceutical Co. Ltd. Class A carries a market capitalization of 3.17B, placing it among publicly traded companies globally. Its enterprise value stands at 3.32B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Zhuhai Rundu Pharmaceutical Co. Ltd. Class A has 334.89M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.41, and the price-to-book ratio stands at 2.94.

As of June 30, 2026, Zhuhai Rundu Pharmaceutical Co. Ltd. Class A trades at an EV/EBITDA multiple of 1,992.11 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 1,992.11 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.32B versus a market cap of 3.17B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Zhuhai Rundu Pharmaceutical Co. Ltd. Class A maintains a current ratio of 1.69, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 42.26, indicating elevated leverage, while an interest coverage ratio of 0.13 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Zhuhai Rundu Pharmaceutical Co. Ltd. Class A posted a negative return on equity (ROE) of -0.55, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.29, reflecting losses generated across the asset base. The company generates approximately 744,871.13 in revenue per employee across its workforce of 1,737.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.90 indicates how many times Zhuhai Rundu Pharmaceutical Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Zhuhai Rundu Pharmaceutical Co. Ltd. Class A recorded 2.50M in income tax expense. The company reported a pretax loss of -3.60M and -6.09M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Zhuhai Rundu Pharmaceutical Co. Ltd. Class A's stock has declined approximately 29.34% over the past 52 weeks. The 50-day moving average sits at 11.00, while the 200-day moving average is 12.32.

Over the twelve months ended June 30, 2026, Zhuhai Rundu Pharmaceutical Co. Ltd. Class A generated 1.29B in revenue and converted that into -6.09M in net income, yielding earnings per share of -0.02. EBITDA reached 1.66M, while operating income came in at 61.94M.

As of June 30, 2026, Zhuhai Rundu Pharmaceutical Co. Ltd. Class A holds 308.06M in cash and equivalents against 456.09M in total debt, resulting in a net debt position of 53.61M. Total book value stands at 1.08B, with working capital of 378.12M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Zhuhai Rundu Pharmaceutical Co. Ltd. Class A posted a gross margin of 40.27, reflecting its pricing power and cost economics. The operating margin of 4.79 and net profit margin of -0.47 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Zhuhai Rundu Pharmaceutical Co. Ltd. Class A paid dividends of 0.19 per share. The dividend payout ratio of -1,030.42 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.68, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zhuhai Rundu Pharmaceutical Co. Ltd. Class A shareholders.

Zhuhai Rundu Pharmaceutical Co. Ltd. Class A's most recent stock split took place on May 31, 2023 with a 5:7 split ratio.

As of June 30, 2026, Zhuhai Rundu Pharmaceutical Co. Ltd. Class A has an Altman Z-Score of 3.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.